2018) Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy, OncoImmunology, 7:1, e1376153, ABSTRACT Extracellular vesicles (EVs) have been discussed as a diagnostic tool for minimal residual disease (MRD) evaluation in breast cancer (BC) in addition to the analysis of circulating tumor cells (CTCs). Therefore, we investigated circulating EV levels as surrogate markers for disease monitoring and prediction of prognosis in primary, non-metastatic, locally advanced BC patients.
Introduction
Primary, non-metastatic breast cancer (BC) is considered as a systemic disease rather than a local disease, which implicates the requirement of early systemic, neoadjuvant therapies for treatment of systemic disease spread. 1 Originally, neoadjuvant chemotherapy (NACT) was used for the treatment of locally advanced and non-operable tumors, but presently, NACT has become a standard treatment in primary BC. 1, 2 Depending on the intrinsic BC subtype, a pathological complete response (pCR) can be achieved in a range from 7.5 -36.4% being associated with an improved progression-free (PFS) and long-term survival. 3, 4 Despite high overall survival (OS) rates, a metastatic relapse occurs in 20% of all BC patients. 3 Routine BC diagnostics do not elucidate the complex intratumor heterogeneity and explain BC tumor biology. Therefore, potent non-invasive biomarkers are needed to assess the risk of recurrence. Extracellular vesicles (EVs) and circulating tumor cells (CTCs) have been discussed to be promising candidates. 5 For CTCs, the prognostic relevance has even already been demonstrated in early BC. 6, 7 EVs, such as exosomes and microvesicles, could be of further interest and relevance. These vesicles are released by all cell types including tumor cells and can be isolated from all body fluids. 8 EVs are able to fuse with local or distant recipient cells thereby altering their cellular phenotypes and biological properties. 9, 10 In vitro studies demonstrated that EVs derived from tumor cell lines contribute to tumor invasion, 11 chemoresistance, 12, 13 angiogenesis, 14 metastasis or immune escape. [15] [16] [17] BC-derived EVs are able to induce a neoplastic phenotype in fibroblasts 18 and mesenchymal stem cells. 19 EVs shed by BC cells are able to interact with normal breast cells, enhancing their proliferation, migration and invasiveness. 20 Further, BC-derived EVs can mediate drug resistance transfer from chemotherapy resistant BC cells to non-resistant BC cells via P-Glycoproteins or micro-RNAs. [21] [22] [23] Additionally, BC specific targeted drugs are reported to be neutralized by EVs expressing the drugs' target protein. 24 Clinical studies analyzing tumor-derived EVs associated biomarkers have been conducted for quite a few tumor entities. 25 Up to now, we are not aware of any study analyzing the circulating EV concentration and size from BC patient samples. In our study, we enriched and analyzed for the first time the circulating EVs from 105 paired, locally advanced, NACT treated BC patients before and after therapy. We analyzed the recorded EV parameters in association with i) routinely determined clinical BC parameters, ii) their prognostic significance regarding PFS and OS and iii) CTC presence.
Results

Characterization of EVs in BC patients and healthy females
To verify the presence of EVs in the samples, SDS-Page and western blot ( Fig. 1A) were performed for the detection of typical EV markers that included the tetraspanins CD9, CD63, CD81, ESCRT-associated proteins TSG101 and Syntenin as well as HSP70. Cytochrome C served as a negative control for cellular protein contamination. 26, 27 Characteristic EV markers were present in all sample preparations, but in different expression levels (Suppl. Table 1 ). The absence of Cytochrome C detection from EV samples of BC patients and healthy controls demonstrate that the samples were free of cellular protein contamination. Nanoparticle tracking analysis (NTA) revealed that EV particles size did not differ between pre-or post-NACT BC patient samples ( Fig. 1B ), whereas the EV particle concentration differed substantially (Fig. 1C ). Healthy females displayed 40-fold lower EV particle concentrations in comparison to BC patient samples procured before and after therapy (p < 0.0001). Overall, the EV particle concentrations were significantly (p D 0.0082) increased in BC samples obtained post-NACT compared to pre-NACT. With the exception of patients who underwent hormonal therapy or chemotherapy combined with Avastin the clinical subgroup analyses revealed elevated EV levels after NACT without always reaching statistical significance (Suppl. Table 2) .
Increased EV concentrations pre-NACT are associated with lymph node infiltration and therapy failure The association of EV particle concentrations obtained preand post-NACT with clinical parameters (Table 1) showed that pre-NACT EVs levels increased with the number of infiltrated axillary lymph nodes pre-and post-NACT (p < 0.05). BC patients who did not respond to NACT, showed significantly (p < 0.05) higher pre-NACT EV concentrations compared to patients responding to the therapy. All other clinical parameters were not related to the EV concentration pre-NACT.
Increased EV concentrations post-NACT are associated with ER expression as well as reduced three-year progression-free and overall survival Samples from post-NACT BC patients whose tumors were estrogen-receptor (ER) positive showed significantly (p < 0.05) elevated circulating EV concentrations when compared to (Table 1) . Further, the post-NACT EV concentration was associated with a reduced 3y-PFS and OS. A lower EV concentration post-NACT was related to survival of BC patients (p < 0.05) and the same was observed regarding 3y-PFS (p < 0.01). No association between EV particle concentrations determined post-NACT and other clinical parameters was observed.
Determination of EV concentrations as a prognostic marker for disease progression and outcome
Due to specific associations between EV particle concentrations post-NACT and 3y-PFS, ROC analysis was performed to define an optimal cut-off value (AUC D 0.800, sensitivity: 100.0%, specificity: 55.4%, p D 0.005) for risk assessment regarding progression prediction of BC patients post-NACT ( Fig. 2A ). Kaplan-Meier Curve analyses combined with the log-rank test revealed that EV particle concentrations > 2484 £10 9 EVs/ml post-NACT were significantly [p D 0.003; Hazard Ratio (HR): 8.27, 95% confidence interval (CI): 2.05 -33.32] associated with a reduced 3y-PFS ( Fig. 2B ).
Regarding OS, an identical cut-off value of EV particle concentration post-NACT was calculated by ROC analysis (AUC D 0.734, sensitivity: 100.0%, specificity: 53.6%, p D 0.027, Fig. 2C ). Patients with EV concentrations above 2484 £10 9 incidence of SL-CTC [73%, p D 0.0463], ALDH-1 positivity [86%, p D 0.0367] was higher in patients with EV concentrations below the cut-off value than in the ones above the cut-off. The combination of ALDH-1/ERCC1 positivity (65%, p D 0.0085) was associated in the same manner (Table 2 ).
Discussion
EVs have been reported as important mediators in BC development, maintenance and progression. Therefore, we hypothesize that the number of in vivo circulating EVs reflects the status of MRD and its outcome in BC patients. To the best of our knowledge, we are the first group to demonstrate a clinical relevance of EV concentrations before and after therapy in neoadjuvant treated BC patients. Indeed, the results of our study reveal that i) BC patients have a 40-fold higher EV concentration than healthy females, ii) therapy failure is associated with high EV concentrations pre-NACT, iii) elevated post-NACT EV concentrations are associated with 3y-PFS and OS in patients and iv) circulating EVs are related to post-NACT stem cell-like and/or resistant CTCs. These results have been carved out from a uniform patient cohort in whom the restrictive patient eligibility criteria focused solely on a primary, non-metastatic, locally advanced BC patient cohort with available samples preand post-NACT including a follow-up. The characterization of EVs enriched from BC patient samples was performed according to the current recommendations. 27, 28 We detected different tetraspanins (CD9, CD63, CD81) in varying amounts which might be due to the different compositions of EV sources. All EV samples comprised Syntenin and TSG101, which are ESCRT complex associated proteins or linked to the release of EVs. 29, 30 In contrast, the intracellular protein Cytochrome C was not detectable. Thus, this marker profile showed that EVs are present in our preparations.
The circulating EV concentration was 40-fold elevated in NACT treated BC patients compared to healthy individuals, which was also described by others in BC. 31, 32 Pre-NACT EV concentrations were 1.5 fold increased in BC patients with advanced axillary lymph node spread at both time points compared to patients without lymph node involvement. This observation may indicate that a substantial amount of circulating EVs is released by tumor cells resident in lymph nodes, where an enhanced delivery into the periphery might be conceivable. Similar to pre-NACT, EV concentrations post-NACT were increasing with advanced axillary lymph node infiltration. An association of CTCs and SL-CTCs with lymph node spread was not observed in this cohort. 4 Consequently we hypothesize a different quality of EVs as a complementary marker in BC.
EV concentrations determined pre-and post-NACT have different aspects in patient risk management. BC patients not responding to NACT had 1.6-fold elevated EV concentrations pre-NACT compared to responders, which supports the hypothesis that EVs may be related to therapy outcome. In vitro studies suggested a similar tendency by demonstrating a chemotherapy resistance transfer and neutralizing anti-HER2 treatment by EVs. [21] [22] [23] [24] 33 Post-NACT EV concentrations were associated with BC outcome of a reduced 3y-PFS and OS. Of note, the same cut-off value for EV concentrations post-NACT was obtained regarding 3y-PFS and OS for patient stratification. This also emphasizes the specificity of EV particle concentrations post-NACT as a clinically relevant predictor. In vitro studies demonstrated the induction of a neoplastic phenotype in fibroblasts and mesenchymal stem cells, 19 to enhance proliferation, migration and invasiveness of normal breast cells. 20 High numbers of circulating EVs in BC patients may use these mechanisms for tumor maintenance and spread, which may explain the worse BC prognosis.
An inverse association between CTC subgroups and EV concentrations post-NACT was observed. It is conceivable that remaining stem cell-like or resistant CTCs after NACT may be internalizing EVs for maintaining their BC phenotype. Additionally, the lowering EV concentrations might be due to TME alterations induced by the residual CTCs. The reason for this remains unclear and needs to be further investigated.
Both MRD markers -EVs and CTCswere isolated from one sample clearly comprising different, but complementary information on BC disease status and prognosis. 4 Therefore, the simultaneous analysis of CTCs and EVs depicts an easy tool for completing the information of the MRD status. To this point, only quantitative EV analyses were performed, however providing clinical and prognostic importance. In CTC research, it has been demonstrated, that besides the enumeration of CTCs, their molecular characterization is essential. 4, 34, 35 In future studies, a detailed qualitative analysis of EVs by gene expression analyses via RNA-Seq or on the protein level by mass spectrometry will provide a comprehensive characterization of MRD in BC. The disease monitoring via EV analyses is a meaningful approach as the EV composition appears to reflect the disease status.
Conclusion
Our study highlights that the number of circulating EVs is of clinical and prognostic impact in BC patients. The association of circulating EVs with CTC presence underlines the requirement of analyzing both, EVs and CTCs, from one liquid biopsy for determination of EVs/CTC number and EV size and their molecular characterization. The simultaneous analysis from one sample will provide deeper insights into BC MRD and heterogeneity and facilitate individual patient risk management.
Material and methods
Human subjects and study design
In this study, 105 primary, non-metastatic, locally advanced BC patients treated with NACT at the Department of Gynecology and Obstetrics, University Hospital Essen, from January 2007 until June 2012, were enrolled. All samples were obtained after written informed consent and collected using protocols approved by the institutional review board (05/2856). The patient characteristics are documented in Table 3 . The median follow-up time for 3y-PFS was 34 months (range: 4 to 36 months) and 52 months (range: 4 to 82 months) for OS. Eight patients experienced a disease relapse or died of BC. The patients' eligibility criteria, NACT treatment regimens and definition of NACT response was described in detail elsewhere. 4
Plasma sampling
Ethylenediaminetetraacetic acid blood samples were collected pre-and post-NACT. Blood samples from age-matched, healthy females (n D 16; 47 years) represented the control panel. The blood samples were processed immediately or not later than 4 hours after withdrawal, centrifuged at 1500 g for 10 min and the plasma supernatant was stored at ¡80 C until further usage.
Enrichment of circulating extracellular vesicles
The enrichment and precipitation of circulating EVs was performed using ExoQuick TM precipitation reagent (SBI Systems Bioscience Inc., #EXOQ20A-1) according to the manufacturer's instructions and described elsewhere. 26 Enriched EVs samples were stored at ¡20 C until further processing.
Nanoparticle tracking analysis for EV enumeration and size determination
NTA was performed for determination of size and particle concentration using the ZetaView (Particle Metrix GmbH, Microtrac) with corresponding software (Version 8.02.28) and defined settings: 85% sensitivity; 20% brightness; measuring size range: 5-200 nm. To obtain constant particle concentrations of approximately 1 £ 10 6 /ml in NTA, samples were regularly diluted by a factor of 1:50000 in phosphate buffered saline. In duplicate analysis a mean coefficient of variation for the EV particle concentration of 16.6% and for EV size of 1.8% was achieved. For serial plasma samples of healthy donors (n D 6) procured at least three different time points within one year a mean coefficient of variation for the EV particle concentration of 25.7% and for EV size of 4.4% was achieved
EVs characterization by SDS Page and western blot
EV marker expression was characterized by SDS-Page and western blot analysis under reducing conditions as described elsewhere for expression of CD9, CD63, CD81 and TSG101 (all SBI Systems Bioscience Inc., #EXOAB-KIT-1, #EXOAB-TSG101-1). 26 
Statistical and graphical analysis
Statistical analysis was performed using SPSS 23.0 (SPSS Inc.), GraphPad Prism 7.0 (GraphPad Software) and BIAS 10.12 (Epsilon Verlag). Particle concentrations (10 9 /ml) and sizes (nm) were given as median (interquartile range) or median (range). After testing for Gaussian distribution, the differences between two or more groups were assessed by Mann-Whitney test or Kruskal-Wallis test. In paired analysis Wilcoxon rank sum test was applied. ROC analysis was performed to obtain cut-off values for categorization of continuous patients' characteristics into dichotomous variables representing the optimal separation of survival curve. Kaplan-Meier Curve analysis in combination with the log-rank test was executed for the analysis of 3y-PFS and OS probabilities. The 3y-PFS and OS were measured from time point of diagnosis until 36 months later or death/last contact. For categorical data analysis Fisher's exact test was used. Statistical significance was defined as p 0.05. 
Disclosure of potential conflicts of interest
